BioSpace News Archive

Yesterday, the celebrations for the MALETH project took place with a special keynote presentation from Dr. James Green, NASA’s Former Chief Scientist.

RELIEF THERAPEUTICS Holding SA announced the results of its extraordinary general meeting held today in Geneva and that all proposals were approved by a large majority of shareholders.

Aquavit Holdings (Aquavit), a biotechnology company focused on the development of botulinum toxin applications, announced today that it has filed an Investigational New Drug Application with the FDA for its flagship intradermal injection of botulinum toxin, Dermatox™ (aqubotulinumtoxinA).

Kala Pharmaceuticals, Inc. announced that the California Institute for Regenerative Medicine has awarded Combangio, Inc., a wholly owned subsidiary of Kala, a $15 million grant to support its ongoing KPI-012 program for the treatment of persistent corneal epithelial defect.

Genetic Technologies Limited is pleased to announce the publication of a research paper in the peer-reviewed journal Melanoma Research validating the geneType for Melanoma risk assessment test in one of the most commonly diagnosed cancers in the Western world, 3rd in Australia and 5th in the United States.

Tempest Therapeutics, Inc. today announced positive early results from a global randomized Phase 1b/2 clinical study in which TPST-1120, Tempest’s small molecule PPAR⍺ antagonist, demonstrated clinically-meaningful improvement in multiple categories when combined with the standard-of-care regimen of atezolizumab and bevacizumab in a randomized comparison to atezolizumab and bevacizumab in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).

INOVIO today announced that first quarter 2023 financial results will be released after the market close on May 10, 2023.

How do state laws affect male infertility treatment? How does treatment vary across the country? What is ADAM and what are the results of its first clinical trials?

Spero Therapeutics, Inc. announced that on April 21, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 375,000 restricted stock unit awards to four new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan.

The board of directors of Semler Scientific, Inc., is pleased to announce that it has appointed Doug Murphy-Chutorian, M.D., former CEO and a current member of the board of directors as chief executive officer on an interim basis with immediate effect.